ClinicalTrials.gg
CompletedNCT06011304Updated Sep 29, 2026

Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer

A Phase 3 interventional study of [18F]Florastamin Injection in Prostate Cancer, sponsored by HTA Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by HTA Co., Ltd. · Phase 3, Interventional, and Diagnostic

How we know · 4 judgments

Updated Sep 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
287
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 542 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 52 of them phase 3. Prostatic Neoplasms · China.

Enrollment
107th of 436
287 · median 100
Started
2023
with 58 others
Phase 3
78 of 542
24 open now
Registered
253rd of 542
by date

Among the 542 studies in Prostatic Neoplasms with a site in China, this one is the 107th largest by enrollment of the 436 interventional ones that give a count, is one of 59 that started in 2023, is one of 78 in phase 3, and was the 253rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 542 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

276 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 542 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

In this study, 18F-Florastamin PET/CT will be performed in patients with at least intermediate risk prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.

This study will first carry out the pilot study (including pharmacokinetics and radiation dosimetry).

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects fully understood the content, process, and potential risks of the study and voluntarily signed an form (ICF).
  2. Male subjects aged 18 or older.
  3. Subjects with histopathological diagnosis of prostate adenocarcinoma.
  4. According to clinical judgment, radical prostatectomy and pelvic lymph node dissection (which can include patients with localized, regional lymph node or oligometastatic prostate cancer) are planned, and there is no surgical .
  5. If it is localized prostate cancer, according to the Prostate Cancer Diagnosis and Treatment Guidelines of 2021 Chinese Society of Clinical Oncology, it is necessary to meet any of the following criteria:

    Intermediate Risk: Has at least one intermediate risk factor: T2b-T2c; Gleason pattern 2 or 3; PSA 10-20 ng/mL, and does not include feature of high-risk or very-high-risk groups.

    High Risk: Has no very-high-risk features and has at least one high-risk feature: T3a; Gleason Grade Group 4 or 5; PSA >20 ng/mL.

    Very High Risk: Has at least one of the following: T3b-T4; Primary Gleason pattern 5; More than 4 punctures with Gleason Grade Group 4 or 5.

  6. score 0 or 1.
  7. Subjects who meet the following conditions in hematology, renal function, and liver function:

    • count>100 * 10\^9/L
    • Urea nitrogen and creatinine\<1.5 times
    • and ALT\<2.5 times upper limits of normal.
  8. Expected survival time ≥ 6 months.
  9. Subjects and their partners must use effective measurements and avoid sperm donation from the date of signing ICF to 3 months after administration.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have participated in other interventional clinical trials before signing ICF and were within the 5 half-lives of the drug, or who are currently participating in other interventional clinical trials or have participated in clinical trials of radioactive drugs within 1 year before signing ICF and have been discontinued for less than 3 months until the signing date of ICF.
  2. Intravenous injection of iodinated contrast medium within 24 hours, or any high-density oral contrast medium (Such as barium sulfate. Oral water contrast is acceptable, such as compound meglumine diatrizoate oral liquid) within 5 days, prior to study drug administration.
  3. Subjects administered any high energy (>300 KeV) gamma-emitting radioisotope within five physical half-lives prior to study drug administration.
  4. Patients with prior androgen deprivation therapy or any other agent.
  5. The investigator determines that there are any medical diseases or other conditions that affect the safety or compliance of the subjects.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
287 participants (actual)

Study arms

  • Experimental
    18F-Florastamin Injection

    Drug: [18F]Florastamin Injection

Interventions

  • DrugFlorastaminStudies of FlorastaminFlorastamin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The subjects who participate in phase 3 study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 110 min after the injection. Subjects who participate in pilot study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 5 min, 30 min, 60 min, 110 min, 160 min after the injection.

06

What researchers measure

Primary outcomes

  1. Specificity

    The specificity of 18F-Florastamin PET/CT in patients with negative pelvic lymph node metastasis compared with the histopathology. The subjects underwent RP (radical prostatectomy) with PLND (pelvic lymph node dissection) within 28 days after the administration of 18F-Florastamin Injection. The histopathology results of the pelvic lymph node tissue collected from the subjects will be used as the standard of truth for this study.

    Time frame: Within 28 days following 18F-Florastamin PET/CT

Secondary outcomes

  1. Sensitivity

    The sensitivity of 18F-Florastamin PET/CT in patients with positive pelvic lymph node metastasis compared with the histopathology.

    Time frame: Within 28 days following 18F-Florastamin PET/CT

07

Study locations

1 site
  • Sun Yat-sen University Cancer Center
    Guangzhou, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Apr 2026, 29 months.

Of 127 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 29 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Nov 2024 → Apr 2026 and completion Jan 2025 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2023
First posted
Aug 25, 2023
StartActual
Oct 20, 2023
Primary completionActual
Apr 16, 2026was Nov 2024
CompletionActual
Apr 16, 2026was Jan 2025
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 29, 2026
Primary completion
Nov 2024→Apr 16, 2026 (actual)
Sep 29, 2026
Study completion
Jan 2025→Apr 16, 2026 (actual)
Sep 29, 2026
Enrollment
267 (estimated)→287 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Completed
    Primary completion Nov 2024→Apr 16, 2026 (now actual)
    Study completion Jan 2025→Apr 16, 2026 (now actual)
    Enrollment 267 (estimated)→287 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06011304
Lead sponsor
HTA Co., Ltd.
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
Oct 20, 2023
Primary completion
Apr 16, 2026
Completion
Apr 16, 2026
Last update
Sep 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florastamin

Start the discussion